Physician profile
John E Casilli
NPI 1972044220
$1,793.17
in general payments reported to CMS, 2019-2025
18 companies · $715 in 2025
The $715 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2023: $121 · 2024: $733 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $270.38 | 2024-2025 | |
| Cequr Corporation | $244.23 | 2024-2025 | Cequr Simplicity |
| Mannkind Corporation | $223.18 | 2021 | |
| Sequel Med Tech, LLC | $187.54 | 2025 | Twiist |
| Beta Bionics, INC. | $165.24 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $148.84 | 2025 | Minimed 780g |
| Corcept Therapeutics | $140.01 | 2024-2025 | Korlym |
| Btg International INC. | $121.30 | 2023 | |
| Exact Sciences Corporation | $48.09 | 2024-2025 | Cologuard Collection Kit |
| Insulet Corporation | $45.57 | 2024-2025 | Omnipod |
| Nevro Corp. | $40.91 | 2024 | Senza |
| Inspire Medical Systems, INC. | $37.60 | 2025 | Inspire |
| Novo Nordisk INC | $32.17 | 2024-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.53 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $18.19 | 2025 | Gvoke Hypopen |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.08 | 2024 | Jardiance |
| Lundbeck LLC | $15.67 | 2024 | Rexulti |
| Lilly USA, LLC | $13.64 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Casilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.